Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
NCT03883204, Phase 4, Unknown, Fundación Marques de Valdecilla
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up | ClinicalTrials.gov |
| NCT number | NCT03883204 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 115 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Fundación Marques de Valdecilla | ClinicalTrials.gov |
| Conditions | Schizophrenia, Psychotic Disorders, Psychosis | ClinicalTrials.gov |
| Interventions | Aripiprazole, Risperidone | ClinicalTrials.gov |
| First posted | 2019-03-20 | ClinicalTrials.gov |
| Last updated | 2020-01-14 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Global cognitive index | 3 years | In order to calculate a measure of Global Cognitive Functioning (GCF) raw cognitive scores were reversed when appropriate before standardization so they all have the same direction (the higher, the better). According to previous methodology, the GCF was calculated as T-scores, with raw scores of a healthy comparison sample. T scores were converted to deficit scores that reflect presence and severity of cognitive impairment. Deficit scores on all tests were then "averaged" to create the GCF score. | ClinicalTrials.gov |
| Secondary | Change in information processing speed | 3 years | Measured by Wechsler Adult Intelligence Scale (WAIS)-III digit symbol subtest (standard total score). | ClinicalTrials.gov |
| Secondary | Change in information processing speed | 3 years | Measured by Trail Making Test (TMT) trail A. | ClinicalTrials.gov |
| Secondary | Change in information processing speed | 3 years | Measured by Continuoys Performace Test (CPT) reaction time. | ClinicalTrials.gov |
| Secondary | Change in motor dexterity | 3 years | Measured by Grooved Pegboard Test (time to complete with dominant hand). | ClinicalTrials.gov |
| Secondary | Change in working memory | 3 years | Measured by WAIS-III letter-number sequencing test (standard total score). | ClinicalTrials.gov |
| Secondary | Change in working memory | 3 years | Measured by WAIS-III digits forward (standard total score). | ClinicalTrials.gov |
| Secondary | Change in verbal learning | 3 years | Measured by the Rey Auditory Verbal Learning Test (RAVLT) (trials 1-5). | ClinicalTrials.gov |
| Secondary | Change in visuospatial abilities | 3 years | Measured by the Rey Complex Figure (RCF) (copy figure). | ClinicalTrials.gov |
| Secondary | Change in delayed memory | 3 years | Measured by the Rey Auditory Verbal Learning Test (RAVLT) (list recall and list recognition discrimination subscore). | ClinicalTrials.gov |
| Secondary | Change in delayed memory | 3 years | Measured by the Rey Complex Figure (RCF) (delayed recall). | ClinicalTrials.gov |
| Secondary | Change in attention | 3 years | Measured by Continuoys Performace Test (CPT) (discrimination subscores). | ClinicalTrials.gov |
| Secondary | Change in executive function | 3 years | Measured by Trail Making Test (TMT) trail B. | ClinicalTrials.gov |
| Secondary | Change in executive function | 3 years | Measured by Stroop Test (color-word). | ClinicalTrials.gov |
| Secondary | Change in executive function | 3 years | Measured by the Zoo Map Test (first and second conditions). | ClinicalTrials.gov |
| Secondary | Change in executive function | 3 years | Measured by the Tower of London Test (ToL) (total correct and total moves score). | ClinicalTrials.gov |
| Secondary | Change in executive function | 3 years | Measured by FAS Word Fluency and semantic (animal) fluency tests. | ClinicalTrials.gov |
| Secondary | Change in theory of mind | 3 years | Measured by Eyes Task (total correct score). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Letter-Number Sequencing Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Tower Planning | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)